

Discovery of VRK1 inhibitor for precision medicine of advanced/refractory solid cancer

Korea Reserch Institute Of Chemical Technology(KRICT)



ONCOLOGY	Hit
Product Type	Synthetic small molecule drug
Indication	<ul style="list-style-type: none"> • Advanced/refractory solid cancer - Nervous system cancer: VRK2^{low} proneural subtype GBM - Non-neurological cancer: : FOSL1^{high} liver/pancreatic cancer
Target	VRK1
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • Targeting mitosis through defects in nuclear envelope integrity • Induction of DNA damage response
Competitiveness	<ul style="list-style-type: none"> • First-in-class • Synthetic lethality-driven biomarkers for precision medicine
Development Stage	Hit
Route of Administration	Oral administration